Precision BioSciences
NASDAQ: DTILDurham, US · Delaware corporation · 11 known investors
Precision BioSciences develops gene-editing medicines using its proprietary ARCUS genome editing platform, which employs sequence-specific nuclease enzymes to insert, remove, or repair DNA in living cells to treat hard-to-treat conditions including rare genetic diseases and hepatitis B (HBV).
Founders & leadership
JS
JEFF SMITHCo-founder
DJ
DEREK JANTZCo-founder
MK
MATTHEW KANECo-founder
JS
Jeff SmithCo-founder
DJ
Derek JantzCo-founder
TM
TODD MELBYExecutive
Board
RA
ROBERT ADELMANBoard directorCo-founder and Emeritus Managing Partner at venBio Partners
BA
BEN AUSPITZBoard director
Investors · 11
age1San Francisco · $500K – $4M
Aliment CapitalLos Angeles · $3M – $5M
Brace PharmaAtlanta
F-Prime CapitalCambridge · $3M – $10M
OCV PartnersLos Angeles
OUP (Osage University Partners)Bala Cynwyd · $1M – $20M
Pontifax AgTechSanta Monica
RA CapitalBoston
venBio PartnersSan Franciscovia Robert Adelman · board
Vivo CapitalPalo Alto · $10M – $50M
Agent CapitalreportedWaltham
Reported raises · per SEC filings
Form D private placements$153.3M disclosed across 3 rounds · 2015–2019
▶$39.5MraisedMar 2019 · 23 investors · BiotechnologyRule 506(b)
▶$39.5MraisedMar 2019 · 23 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Derek JantzExecutive Officer, Director
- Matthew KaneExecutive Officer, Director
- Robert AdelmanDirector
- Shalini SharpDirector
- Jeff SmithExecutive Officer
- Abid AnsariExecutive Officer
- Tony YaoDirector
- Offering amount
- $70M
- Amount sold
- $39.5M
- First sale
- Mar 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$88.1MraisedJun 2018 · 40 investors · BiotechnologyRule 506(b)
▶$88.1MraisedJun 2018 · 40 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Derek JantzExecutive Officer, Director
- Tony YaoDirector
- Matthew KaneExecutive Officer, Director
- Abid AnsariExecutive Officer
- Jeff SmithExecutive Officer
- Robert AdelmanDirector
- Offering amount
- $110M
- Amount sold
- $88.1M
- First sale
- May 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$25.6MraisedMay 2015 · 11 investors · BiotechnologyRule 506(b)
▶$25.6MraisedMay 2015 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- JEFF SMITHExecutive Officer
- ROBERT ADELMANDirector
- DEREK JANTZExecutive Officer, Director
- MATTHEW KANEExecutive Officer, Director
- TODD MELBYExecutive Officer
- BEN AUSPITZDirector
- Offering amount
- $25.6M
- Amount sold
- $25.6M
- First sale
- Apr 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapLife Biosciences78 shared keywordsLongevity company with diversified therapies to extend healthy human lifespan
IQVIA76 shared keywordsIQVIA provides data, analytics, AI, and technology-driven services for life sciences and healthcare organizations, spanning clinical development, real world evidence generation, and commercial execution. It offers integrated solutions for clinical trials, regulatory and safety compliance, and market analytics, including agentic AI products for commercial and R&D teams.
Companies competing with Precision BioSciences for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Precision BioSciences do?
- Precision BioSciences develops gene-editing medicines using its proprietary ARCUS genome editing platform, which employs sequence-specific nuclease enzymes to insert, remove, or repair DNA in living cells to treat hard-to-treat conditions including rare genetic diseases and hepatitis B (HBV).
- Who founded Precision BioSciences?
- Precision BioSciences was founded by JEFF SMITH, DEREK JANTZ, MATTHEW KANE, Jeff Smith, Derek Jantz.
- Who are Precision BioSciences's investors?
- Precision BioSciences's investors include age1, Aliment Capital, Brace Pharma, F-Prime Capital, OCV Partners, OUP (Osage University Partners), Pontifax AgTech, RA Capital and 3 more.
- How much funding has Precision BioSciences raised?
- Precision BioSciences has disclosed $153.3M raised across 3 rounds.
- Where is Precision BioSciences headquartered?
- Precision BioSciences is headquartered in Durham, US.